Trial Profile
Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 17 Mar 2020 Status changed from recruiting to completed.
- 13 Jun 2017 New trial record